Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

USA – FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe

The FDA’s required label update comes less than two months after the agency unveiled an investigation into secondary T-cell malignancies among patients who received BCMA- or CD19-targeted CAR-Ts.

For all six commercial CAR-T therapies, the FDA is requiring label updates to include T-cell malignancies in the boxed warning section of each product’s label, according to the agency’s separate notification letters dated Jan. 19 to Bristol Myers Squibb, Gilead Sciences’ Kite Pharma, Johnson & Johnson and Novartis. A black box warning is the most serious safety alert on a medication’s label.

More information on Fierce Pharma.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (24 juillet 2024). USA – FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/12365


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.